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Background: Human chromosome arm 3p is often affected in various epithelial tumors, and several tumor suppressor genes were 
recently identified in this region. The most affected is 3p21 region that is 50–100% rearranged in more than 30 types of malignan-
cies, mostly in epithelial cancers: lung, breast, ovarian, cervical, kidney, head and neck, nasopharyngeal, colon etc. These cancers 
are responsible for 90% of cancer deaths. Aim: To perform the detailed analysis of 3p (especially 3p21 region) to discover novel 
potential oncogenes and/or tumor suppressors. Methods: To find novel “hot spots” and genes involved in major cancers, dense 3p 
microsatellite markers (altogether 24 ) were allelotyped in four epithelial carcinomas (272 patients in total): breast (BC), renal cell 
(RCC), non-small cell lung (NSCLC) and epithelial ovarian (EOC) cancers. Results: As a main result, a novel region, frequently 
affected in BC, RCC, NSCLC and EOC was localized between markers D3S2409 and D3S3667 in the 3p21.3. This region 
(MECA3, major epithelial cancers affected region No. 3) covers numerous UniGene clusters, including genes involved in vital 
cell functions and carcinogenesis (e.g. MST1, MSTR1/RON, GPX1 and RHOA). The homozygous deletions were detected in the 
GPX1 in RCC (12%, 6 of 50 cases) and BC (1 of 37 cases). At the same time, amplifications and multiplications within the RHOA 
putative oncogene were identified in BC and RCC. Conclusions: The data suggest that genes with potential oncogenic features are 
located in the close proximity to putative tumor suppressor gene(s) (TSG(s)) in the MECA3. Multiplication of the RHOA was not 
reported before. Significant correlation of allelic alterations in the, AP20, MECA3 and LUCA regions with tumor progression was 
found for some common histological tumor subtypes (e.g. clear cell RCC, and serous EOC).
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Carcinogenesis is a multi-step genetic process that 
involves mutational activation of proto-oncogenes and 
inactivation/silencing of tumor suppressor genes 
(TSGs). Identification of genes causally related to the 
neoplastic process is essential to elucidate signaling 
pathways in oncogenesis. Additionally, these genes 
and their products could be used to design new cancer 
biomarkers to improve early diagnosis, predict treat-
ment strategies and disease course.
Epithelial cancers comprise majority of all human 
malignancies and are associated with a high risk of poor 
prognosis. The short arm of chromosome 3 (3p) is fre-
quently involved in the origin and/or development of nu-
merous common solid tumors [1]. Transfer of 3p sub-
chromosomal fragments via microcell hybrids indicated 
that different regions of normal 3p could suppress tumor-
igenic phenotype of cancer cell lines. The data describing 
3p alterations in lung, kidney and other epithelial cancers 
appeared long ago [1]. However, only recently significant 
progress has been achieved in identifying candidate for 
TSG(s) and their role in oncogenesis [2–4]. For some 
of these genes (e.g. RASSF1A, RASSF1C, NPRL2/G21, 
RBSP3/HYA22, SEMA3B, SEMA3F, FUS1 and others) 
tumor suppression activity was demonstrated [3–10].
Loss of heterozygosity and allelic imbalance (AI) 
of polymorphic markers were frequently observed 
in several chromosome 3p regions in various tumors, and 
these observations were commonly used for localization 
and positional cloning of TSG(s). However, since various 
groups applied different subsets of 3p polymorphic mark-
ers, comparison of these data was seriously complicated 
[1, 3]. It seems reasonable to apply an identical marker set 
to compare genomic alterations of 3p in different tumors. 
Since 3p spans up to 100 Mb most likely some crucial sites 
simply remain unknown. In our previous studies we com-
pared chromosome 3p in three cancer types: clear cell 
renal cell carcinoma (RCC), breast (BC) and non-small cell 
lung (NSCLC). Common and cancer specific “hot spot” 
regions were mapped in 3p using identical polymorphic 
markers [11, 12]. Results of 3p microsatellite analysis were 
consistent with Real time PCR assay data [13, 14].
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In this work identical and dense 3p markers and 
representative subsets of tumors (272 patients in total) 
were examined in four cancer types: BC, RCC, NSCLC 
and epithelial ovarian carcinoma (EOC). AI frequen-
cies were compared in four/five common epithelial 
tumors. This allowed identifying four major affected 
regions: LUCA, AP20 and RARβ2 gene regions that 
were defined previously [1–4], and a novel critical region 
of 600 kb size located in 3p21.31 between D3S2409 and 
D3S3667 markers. This region was named MECA3, 
major epithelial cancers affected region in 3p21.3 No. 3. 
The peak around MECA3 was proven statistically  using 
Fisher exact test (P < 10-3). Copy number assay 
of GPX1 and RHOA resident genes suggested close 
location of putative TSG(s) and oncogene(s) within 
this genomic segment. Significant correlation of allelic 
alterations in the main critical 3p regions with tumor 
progression was found for common histological tumor 
subtypes (clear cell RCC, serous EOC, and ductal BC).
MATERIALS AND METHODS
Tissues and DNA samples. Tissues were taken 
from patients not treated by radio- or chemotherapy. 
The study was approved by Ethical Committee, and 
each patient gave a written consent. Tumors were 
classified by TNM and stage according to UICC [15]. 
Histological typing of tumors was performed in accor-
dance with international protocols [16–18]. 95 BC cases 
included mainly ductal (65 cases) and lobular (20 cases) 
breast carcinomas; 80 RCC cases were represented 
by clear cell histology type only; 47 NSCLC were rep-
resented by squamous cell lung cancer (38 cases) and 
adenocarcinoma (9 cases); 50 EOC consisted of diverse 
histological types, including 32 cases of serous adeno-
carcinoma. Patients of each tumor type were divided 
into clinical sub-groups using TNM stages (I+II vs. 
III+IV), tumor malignancy grade (1 + 2 vs. 3), or level 
of tumor differentiation (high (H) + medium (M) vs. low 
(L)). To compare the main clinical groups (early and 
more advanced tumors) and to use more representative 
subsets, stages I, II a, II b, III, a, b, c, and IV were not 
considered separately. The same approach was used 
in regard to differentiation level or tumor grades. 
Top and bottom sections (3–5 �m thick) cut from 
frozen tumor tissues were examined by staining with 
haematoxylin and eosin. Selected samples (contain-
ing 70% or more tumor cells) and matched normal 
control tissues were stored at -70 oC. DNA was isolated 
by overnight treatment with proteinase K at 50 oC, fol-
lowed by phenol/chloroform extraction and precipita-
tion with ethanol. DNA preparations were examined 
by electrophoresis in 0.8% agarose gels. DNA con-
centration was measured in comparison to λ-phage 
DNA (Fermentas, Vilnius, Lithuania).
Polymorphic microsatellite markers and analy-
sis of allelic alterations. The order of polymorphic 
markers on 3p, used in this study, was based on NCBI 
data (Build 33) and UCSC Browser data (Fig. 1). Primers 
for microsatellite markers were from GenBank Amplicon 
databases. Location of marker NL1-024/D3S4285 and 
primers for this locus were determined in our previ-
ous studies [19–22]. PCR and polyacrylamide gel 
electrophoresis were performed as described earlier 
[11]. Band intensities for PCR products of high and low 
molecular weight alleles in tumor and matched normal 
DNA were compared using a Molecular Dynamics Per-
sonal Densitometer SI (Sunnyvale, CA, USA) according 
to the manufacturer’s protocol. Loss of one allele was 
scored only in case when reduction of intensity of this 
allele was more than 50%. Amplification of the second 
parent allele was scored when its intensity in tumor DNA 
was increased two folds or more. PCR was performed 
using Perkin Elmer 2 (Wellesley, MA, USA) and Tercik 
(DNA-Technology, Moscow, Russia) cyclers.
Multiplex PCR with microsatellites and non-
polymorphic gene-markers. Multiplex PCR was 
used to confirm amplification events, allelic losses and 
to analyze copy number changes of fragments within 
RHOA and GPX1 genes in some tumor cases. Multiplex 
PCR with polymorphic loci was performed in conditions 
suitable for the three markers D3S2406, p33715 and 
D3S2456 used in these studies. The PCR reactions 
were performed in a total volume of 50 μl containing 
1× Taq PCR buffer [67 mM Tris-HCl, рН 9.3, 16.7 mM 
(NH4)2SO4, 0.01% Twin-20], 2.0 mM MgCl2, 20 pmole 
of primer per reaction, 250 μM dNTPs, 2U Taq poly-
merase (Fermentas), and 0.1 μg DNA as follows: 95 oC, 
5 min; 35 amplification cycles (94 oC, 25 s; 58 oC , 
1 min; 72 oC, 40 s) and 72 oC, 5 min. PCR products 
were analyzed using 1.5% agarose gel.
The fragment of the exon 3 of the RARβ2 gene 
was used as an internal control in the analysis of copy 
number changes for RHOA, GPX1, RASSF1A and 
SEMA3B. Two primer pairs were used to detect homo-
zygous deletions within GPX1, RASSF1A and SEMA3B.
The PCR reactions were performed in a total volume 
of 30 μl containing appropriate 1 × Taq PCR buffer, 
MgCl2, 20 pmole of primer per reaction, 250 μM dNTPs, 
2U Taq polymerase (Fermentas), and 0.1 μg DNA. Prim-
ers and other conditions are given in Table 1. 
Table 1. Markers used for gene copy number experiments using multi-
plex PCR
Gene marker* Primers Tann/Mg, mM**
PCR pro-
duct, bp
GPX1 ACTTTGTTGTAACTGGGTCTTG
TGTCCTGTGTCATTGTCATTT
55 °C
1.5
548
GPX1-int CGGGTGCGGTGGCTCATA
TGGCGCAATCTAGGCTCACTG
60 °C
1.5
237
RASSF1A GTAAAGCTGGCCTCCAGAAACACGG
GCAGCTCAATGAGCTCAGGCTCCCC
65 °C
2.5***
357
RASSF1A-int GGGGTGGGGTGTGAGGAGGGGACGAA
GGGCGGCGGGAAGGAGCTGAGGAGA
64 °C
1.5
150
SEMA3B TTGAGATATTGGAGTCCACGGGTG
CAGTGTTGGCCTGGAAGACCTC
56 °C
1.5
450
SEMA3B-int CCTTTGCCTGCTGAGCCCCTGGAG
ACCGCCCGCCGTGCCGTAAAGT
64 °C
1.5
242
RHOA GGGAAGCCGAGCACCACCAG
GCTCGGGCGCACTCTCCAG
64.2 °C
3,0***
437
Control, exon 
3 of RARβ2
AGAGTTTGATGGAGTTGGGT
CATTCGGTTTGGGTCAATCC
62 °C
1.5
229
Note: *Fragments from the 5’-region of given genes were studied if not other-
wise mentioned; **Buffer contained 60 mM Tris-HCl, рН 8.5, 10 mM 2-mercap-
toethanol, 25 mM КСl, 0.1% Triton Х-100 if not mentioned otherwise; ***Buf-
fer contained 67 mM Tris-HCl, рН 8.9, 16.7 mM (NH4)2SO4, 0.01% Tween-20. 
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PCR amplifications of RASSF1A and RHOA 
were performed under the program: 95 oC, 5 min; 
30 amplification cycles (94  oC, 30 s; 63  oC, 40 s; 
72  o C, 35 s) and 72  oC, 5 min. For GPX1 and SEMA3B 
the following program was used: 95 oC, 5 min; 28 am-
plification cycles (94 oC, 25 s; 58  oC, 30 s; 72  oC, 25 s) 
and 72  oC, 5 min. PCR products were analyzed using 
1.5% agarose gel.
In these experiments Tercik (DNA-Technology) 
cycler was used. The band intensities of PCR products 
were analyzed with Video-system Gel Imager and Gel 
Imaging and Gel Analysis (DNA-Technology, Moscow, 
Russia) software.
Statistical calculations. Statistical analysis was 
usually performed using Fisher exact test. Standard de-
viations (SD) for average values of AI frequencies in 3p re-
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Fig. 1. Allelic alterations in 3р polymorphic markers in different tumors. (a) BC (95 cases); (b) RCC (80 cases); (c) EOC (50 cases); 
(d) NSCLC (47 cases). Black circles — loss of one allele; open circles — retention of both alleles; black triangles — loss of one allele 
with the simultaneous amplification of another allele; informative events are shown only. Diff-tion — a level of tumor differentiation 
in abbreviated form. H, M, and L indicate high, medium, and low level of tumor differentiation, respectively; 1, 2, 3 denote tumor 
malignancy grade. The main TNM stages (I, II, III, IV) were also shown. Cases with the increasing number of allelic imbalance (AI) 
events were localized from the left to right within the clinical variable sub-groups
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gions (CI, confidential interval, 95%) were calculated 
as 2{p(1-p)/2n}1/2, where n is the number of informative 
events and p is the average values of AI frequencies [23]. 
RESULTS
Pattern of AI in 3p in five epithelial tumor types. 
The set of identical 3p markers were used to examine 
the representative subsets of RCC, BC, NSCLC and 
EOC samples. As shown on Fig. 2, patterns of allelic al-
terations were mainly represented by loss of one allele, 
and allelic losses accompanied by amplifications of the 
second allele. Allelic imbalances (AI) events in the 3p 
loci were summarized in Fig. 1. Percentage of tumor 
cases with allelic losses was high: 93% (74/80) in RCC, 
88% (84/95) in BC, 84% (42/50) in EOC and 79% 
(37/47) in NSCLC. It is believed that terminal deletions 
appear from mitotic recombination [24, 25]. Interstitial 
deletions can indicate location of TSG(s). Terminal 
deletions were found rather frequent in RCC (29%) and 
NSCLC (34%) only. Multiple interstitial deletions were 
in prevalence to terminal deletions in each tumor type 
under the study: 64% vs. 29% in RCC, 45% vs. 34% 
in NSCLC, 85% vs. 3% in BC, 82% vs. 2% in EOC and 
77% vs. 2% in CC (P << 0.05). These results indicate 
the existence of several putative TSG(s) in chromo-
some 3p.
15
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Fig. 2. Examples of various AI events, including allelic losses, 
loss of one allele with the simultaneous amplification of another 
allele, retention and non-informative cases 
Chromosome 3p “hot spots” affected in major 
epithelial tumors. The AI frequencies were scored 
in four tumor types for the 3p markers to estimate the 
contribution of different regions of 3p to various tumor 
types (Table 2). To localize novel region(s) potentially 
harboring TSG(s) or protooncogene(s), the values 
of AI frequencies in the peaks were compared with the 
average values for the 3p markers scored for the cor-
responding tumor type (see Table 2, bottom). In AI pro-
Table 2. Allelic imbalance frequencies in epithelial tumors (*)
3p SUB-REGIONS** MARKER LOCATION*** RCC (80 cases) NSCLC (47 cases) BC (95 cases) **** EOC (50 cases)
#1 D3S2405 3p25.3 37/48, 77% 19/34, 56% 31/72, 43% 10/27, 37%
D3S1317 3p25.3 35/49, 71% 19/33, 58% 22/63, 35% 8/21, 38%
D3S1038 3p25.3 35/50, 70% 13/30, 43% 15/44, 34% 8/21, 38%
#2 D3S1286 3p25.1 30/55, 55% 23/42, 55% 26/71, 37% 14/42, 33%
#3 D3S1283 3p23 34/49, 69% 19/37, 51% 29/60, 48% 13/27, 48%
D3S3047 3p22.3 33/44, 75% 18/33, 55% 32/60, 53% 17/36, 47%
#4
(AP20)
D3S4285 3р21.33 22/27, 81%, 9/18, 50% 19/41, 46% 10/18, 55%
D3S1298 3p21.33 32/48, 67% 17/31, 55% 29/58, 50% 11/26, 42%
#5 D3S3527 3p21.33 43/59, 73% 14/33, 42% 24/71, 34% 15/37, 41%
P33715 3p21.31 20/33, 61% 9/25, 36% 26/52, 50% 12/24, 50%
D3S1767 3р21.31 33/49, 67% 14/27, 52% 25/52, 48% 9/21, 43%
D3S2420 3р21.31 35/45, 78% 16/35, 46% 27/68, 40% 18/37, 49%
#6
(MECA3)
D3S2409 3р21.31 29/42, 69% 19/32, 59% 39/69, 57%§ 18/37, 49%
D3S2456 3р21.31 35/45, 78% 12/28, 43% 33/59, 56%§§ 17/37, 46%
D3S3667 3р21.31 30/45, 67% No data 34/59, 58%§§§ 11/22, 50%
#7
(LUCA) D3S4614 3p21.31 41/60, 68% 17/34, 50% 36/75, 48%, 17/41, 41%
#8 D3S3615 3р21.2 30/48, 63% No data 15/37, 41% 8/21, 38%
D3S1578 3р21.2 No data No data No data 14/34, 41%,
D3S1766 3р21.1 31/49, 63% 15/32, 47% 20/54, 37% 12/25, 48%
D3S1300 3p14.3 24/33, 73% 7/18, 39% 6/20, 30% No data
D3S1481 3p14.3 29/55, 53% 21/42, 50% 22/68, 32% 14/38, 37%
#9 D3S1285 3р14.2 13/24, 54% 10/25, 40% 4/15, 27% No data
D3S2454 3р14.1 17/35, 49% 11/21, 52% 19/48, 40% 11/28, 39%
D3S2406 3p13 33/60, 55% 12/33, 36% 25/75, 33% 13/37, 35%
Average values 3р25.3-3p13 703/1052,67 ± 2%#
314/643,
49 ± 3%#
558/1290,
43 ± 2%#
280/657,
43 ± 3%#
Note: *AIs divided by informative events number; SD (CI=95%) for the AI average values were scored as 2{p(1-p)/2n}1/2; AI frequencies high-
er than the average values were shown grey; **Twenty three markers were grouped in nine regions of 3p; ***Markers location was from NCBI 
(http://www.ncbi.nlm.nih.gov/cgi-bin/Entrez/map_search), Build 33; ****Significant differences between AI frequencies and average values were found for 
D3S2409, D3S2456 and D3S3667 markers in BC, using Fisher exact test: §P= 0,0206; §§Р = 0,0373;§§§Р = 0,0199.
Table 3. Average frequencies of AI events in nine 3p regions in four cancer types 
Regions
#1 #2 #3 #4 #5 #6 #7 #8 #9
3p25.3
VHL-region 3p25.12-region
3p23-p22.4
RARβ2-region
3p21.33
AP20-region
3p21.33-p21.31
CER-region
3p21.31
MECA3-region
3p21.31
LUCA-region
3p21.2-p14.3
FHIT-region
3p14.2-p13
DUTT1-region
RCC 107/147
73%
30/55
55%
67/93
72%
54/75
72%
131/186
70%
94/132
71%
41/60
68%
114/185
62%
63/119
53%
NSCLC 51/97
53%
23/42
55%
37/70
53%
26/49
53%
53/120
44%
31/60
52%
17/34
50%
43/92
47%
33/79
47%
BC 68/179
38%
26/71
37%
61/120
51%
48/99
48%
102/243
42%
106/187
57%
36/75
48%
63/179
35%
24/65
37%
EOC 26/69
38%
14/42
33%
30/63
48%
21/44
48%
54/119
45%
46/96
48%
17/41
41%
34/84
40%
24/65
37%
Note: The highest average frequencies of AI events for each cancer type in specified regions are shown bold. The average values of AI frequencies in some regions 
were fairly higher (e.g. 5–14% in BC) in comparison with the average value of AI for all 3p markers for a given tumor and exceeded the SD (CI = 95%) for 3p mark-
ers in total (43%, Table 2, bottom). The peak in BC in region #6 (MECA3, D3S2409-D3S3667 interval) was additionally proved, using Fisher exact test with P = 
0.8×10─-3 (106/187, 57% vs. 558/1290, 43%, see Table 2, bottom).
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files of 3p several peaks were found in each cancer. 
Three neighboring markers, D3S2409, D3S2456, and 
D3S3667, located within 3p21.31 band, displayed 
peaks with significant statistics for the representative 
subset of BC patients (P = 0.02–0.04, see Table 2). 
Significant differences between AI frequencies and 
average values were found for D3S2409, D3S2456 and 
D3S3667 markers in BC, using Fisher exact test: P = 
0,0206; Р = 0,0373; Р = 0,0199.
The studied markers were divided into nine groups, 
and the average AI frequencies were scored for vari-
ous regions in each tumor type (see Table 2, 3). This 
approach allowed comparing contribution of diffe rent 
regions along 3p in various tumors. Four regions, 
namely #3, 4, 6 and 7 showed the highest frequen-
cies of AI in all five tumor types. The average values 
of AI frequencies in these regions were fairly higher 
in comparison with the average value of AI in 3p for 
all markers for a given tumor and exceeded the SD, 
CI 95% (see Table 2, 3).
Three regions are located in 3p21.3. Two of them, 
#4 or AP20 (marked by NL1-024/D3S4285 and 
D3S1298) and #7 or LUCA (marked by D3S4614) 
were described earlier [2, 26, 27]. The third frequently 
affe cted region in 3p21.3 (#6, marked by D3S2409, 
D3S2456, and D3S3667), was localized for the first 
time, and importance of this novel site was proven using 
Fisher exact test (P < 10-3; Table 3). According to the 
UCSC Browser data, this D3S2409-D3S3667 region 
(MECA3, major epithelial cancers affected region No. 3) 
covers numerous UniGene clusters (~30 genes/600 kb) 
including genes involved in vital cell functions and 
carcinogenesis, e.g. MST1, MSTR1/RON, GPX1 and 
RHOA. The contribution of these genes in processes 
such as apoptosis, adhesion, signal transduction, an-
giogenesis and others [28–33] was previously reported. 
MECA3 covers region of 600 kb size (49.3–49.9 Mb ac-
cording to the NCBI and UCSC databases), belongs 
to 3p21.31 close to the LUCA region that harbors a clus-
ter of putative and authentic TSG(s) [2–9]. 
Therefore, the regions #3, 4, 6 and 7 (see Table 2, 
3) were frequently affected in all tested major cancers. 
The other regions #1, 5 and 9 (see Table 2, 3) were also 
found involved in some tumors. Region surrounding 
VHL gene (#1, see Table 2, 3) showed AI frequently 
in RCC and NSCLC. Common eliminated region (CER 
or #5, see Table 2, 3) located previously by functional 
assay [34], was significantly affected in RCC and EOC.
Homozygous deletions in GPX1. HDs are excel-
lent indicators for identification of TSGs. Detection 
of HDs was used to discover and confirm AP20 and 
LUCA TSG regions in 3p.21.3 [2, 13, 14]. We screened 
50 RCC and 37 BC cases for HDs within the GPX1 using 
multiplex PCR with two pairs of primers for this gene 
and primers for the exon 3 of the RARβ2 as an internal 
control (see Table 1). Copy numbers of this RARβ2 frag-
ment did not change in RCC and BC cases analyzed 
(Fig. 3, a). HDs were detected within GPX1 gene rather 
frequently in RCC (12%, 6/50), and more rarely in BC 
(3%, 1/37) (see Fig. 3, a). For comparison, RASSF1A 
and SEMA3B from the LUCA region [2–4] were also 
tested (see Fig. 3, b and Table 1; data not shown). 
HDs in GPX1, RASSF1A and SEMA3B were detected 
with similar frequencies. HD incidence was apparently 
tumor and gene specific (see Fig. 3, b). These obser-
vations confirmed the MECA3 as a novel 3p21.3 region, 
potentially harboring TSG(s).
a
b
T
6 26 7 60
N T
RCC BC
N T N T N MK (–)
548 bp
237 bp
229 bp
GPX1
GPX1-int
RAR-β2,
ex. 3
 
Gene Location RCC BC
GPX1 MECA3 6/50, 12% 1/37, 3%
RASSF1A LUCA 0/53, 0% 5/46, 11%
SEMA3B LUCA 4/53, 8% 2/46, 4%
Fig. 3. Homozygous deletions in GPX1 gene resided in the MECA3. 
(a) Representative examples of HDs, detected in GPX1 in RCC 
and BC cases by multiplex PCR. Fragment of 5’-promoter re-
gion of GPX1 was analyzed with two primer pairs and fragment 
of RARβ2 (exon 3) was used as internal control. Primers, PCR 
conditions and programs are shown in Table 1; 1.5% agarose 
gel electrophoresis was used (see also Materials and Methods 
part). (b) Comparison of HDs incidence in GPX1, and RASSF1A 
and SEMA3B (TSGs in the LUCA region) in RCC and BC
Amplification events accompanying allelic 
losses in 3p markers. As it was mentioned above, 
sometimes allelic losses were found associated with 
amplifications of a second parent allele. Amplification 
events (see Fig. 1, 2) were detected in 13% (141 am-
plification events of 1052 informative events) of RCC, 
10% (130/1290) of BC, 8% (52/643) of NSCLC, and 
in 9% (60/657) of EOC. 
Amplification events can activate protooncogene(s) 
located closely to inactivated TSG(s). The non-random 
distribution of amplification events along 3p was ob-
served in various cancers. The enhanced amplifica-
tion frequencies within the MECA3 were proved in BC 
(Fig. 2, a). Amplification events in the MECA3 con-
stituted 16.5% (31/187, for three markers D3S2409, 
D3S2456 and D3S3667; Fig. 1, a), that significantly 
higher than the average value (10%, 130/1290) for all 
3p markers analyzed (P = 0.03). We suggested that 
3p and especially the MECA3 region include putative 
oncogene(s) possibly located closely to TSG(s). 
Amplification of RHOA/ARHA in RCC and 
BC. Multiplication of a particular protooncogene 
in tumors can be one of the reasons leading to its 
activation. Multiplex PCR was applied in this study 
to measure copy number changes of the RHOA 
in RCC and BC cases. RHOA covers D3S2409 and 
is adjacent to the D3S2456. Allelic amplifications were 
revealed for these markers in experiments described 
above (see primers in Table 1). Tumor cases showing 
amplifications with these markers were tested to con-
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firm RHOA multiplication. Exon 3 of the RARβ2 gene 
was used as internal control. RHOA gene revealed 
clear copy number multiplications (data not shown). 
Altogether we found RHOA multiplication /amplifica-
tion varying in range 2–50 times in 12 of 17 RCC and 
in 14 of 19 BC cases. The finding confirmed an ampli-
fication in the MECA3 region in BC and RCC and sup-
ported putative oncogenic features of the RHOA gene.
Contribution of 3p allelic alterations into cancer 
progression. To examine contribution of 3p allelic 
alterations into cancer progression the most common 
histological subtypes like clear cell RCC, ductal and 
lobular BC, serous ovarian adenocarcinoma (serous 
EOC) and squamous cell lung cancer were analyzed. 
The number of affected tumor samples in a given region 
was divided by the total number of tumor samples and 
compared between groups with various clinical stage 
and grade or differentiation (Table 4). In summary, al-
lelic alterations in three most important 3p21.3 regions 
(AP20, LUCA, and MECA3) significantly correlated with 
tumor progression of specific histological subtypes.
Correlations were estimated to be stronly sig-
nificant for AP20 and LUCA regions in clear cell RCC 
(Table 4, a), serous EOC (Table 4, b), and ductal BC 
(not shown), and also for AP20 — in squamous cell 
NSCLC (not shown). The MECA3 was significantly 
associated with advanced clinical stages and low dif-
ferentiation of serous EOC (see Table 4, b). 
Table 4. Correlation of allelic alterations with tumor progression in clear cell 
RCC (A) and serous ovarian adenocarcinoma (B), revealed in 3p regions
a, Clear cell RCC
#4
(AP20)
#7
(LUCA)
Grade P = 0.0421 P = 0.2734
1+2 48%, 20/42 45%, 19/42
3 71%, 27/38 58%, 22/38
Stage P = 0.0117 P = 0.0248
I+II 47%, 22/47 40%, 19/47
III+IV 76%, 25/33 67%, 22/33
b, Serous ovarian adenocarcinoma
#4
(AP20)
#6
(MECA3)
#7
(LUCA)
Differentiation P = 0.0078 P = 0.006 P = 0.0496
H+M 8%, 1/12 33%, 4/12 8%, 1/12
L 60%, 12/20 85%, 17/20 45%, 9/20
Stage P = 0.4501 P = 0.0018 P = 0.2593
I+II 27%, 3/11 27%, 3/11 18%, 2/11
III+IV 48%, 10/21 86%, 18/21 38%, 8/21
Note: The percentage of tumor samples with AI in a given region relative 
to the total tumor samples is shown for early and advanced clinical and his-
tological groups. Statistically significant values are shown bold.
DISCUSSION
Multiple interstitial deletions in 3p and location 
of several TSG(s). In this study we used an additional 
tumor type (EOC) and novel patients compared to our 
previous study [12] that was highly helpful to reduce 
misinterpretation of the mapping data. Fraction of ter-
minal deletions became reduced, e.g. in RCC 29% 
vs. 50%. Discontinuous deletions were also reported 
earlier in previous studies [1, 12–14, 35–38]. Here 
prevalence of multiple interstitial deletions over ter-
minal deletions was highly significant (P < 0.05) in all 
four analyzed tumor types. Frequent interstitial dele-
tions were suggested to indicate a location of several 
cancer related genes in chromosome 3p [1, 3]. This 
hypothesis was recently confirmed by discovery of two 
clusters of putative and authentic TSG(s) in LUCA and 
AP20 sites [2–4, 7–10].
Novel 3p21.3 MECA3 region contains cancer 
related genes including putative TSG(s). Densely 
distributed polymorphic markers gave us the basis 
to compare 3p alterations in four cancer types and 
to define four regions the most frequently affected 
in major epithelial tumors. The use of 13 markers for the 
3p21 band, which was previously shown to be the most 
significant for malignant transformation [1, 3], allowed 
us to delineate at least three important regions inside 
this band. One of these regions, MECA3 between 
D3S2409 and D3S3667 was identified here for the 
first time. The position of the MECA3 was consistent 
with the highest LOH frequency in 3p21.3, reported for 
BC earlier [38]. Our studies provided first statistically 
significant evidence for the AI peak in MECA3 (P < 
0.001). The results suggested that the MECA3 could 
harbor TSG(s). According to the UCSC Browser 
data, numerous UniGenes clusters are located in the 
MECA3 including genes (e.g. RHOA/ARHA, GPX1, 
MST1, MSTR1/RON, USP4 and DAG1) involved in vital 
cell functions (such as apoptosis, adhesion, signal 
transduction, angiogenesis and others) related to ma-
lignant transformation or tumor progression [28–33].
Antioxidant selenoprotein GPX1 metabolizing 
H2O2 to O2 and H2O represents the most commonly 
expressed member of the glutation peroxidase gene 
family. The protein is localized in mitochondria, nucleus 
and cytosol [39]. Decreased expression of GPX1 was 
reported in various tumors [29, 40, 41]. GPX1 plays 
a central role in protection of cells against oxidative 
damage [29, 39]. Down-deregulated expression can 
indirectly point to tumor suppressive features. Indeed, 
GPX1 over-expression was found to delay growth of the 
endothelial cell line, ECV304 [42]. Relation of GPX1 ac-
tivity with malignancy is also based on p53 inducible 
activation of GPX1 transcription through the interaction 
of its promoter region with p53 as a transcription factor 
[43]. One of the reasons leading to the loss of expres-
sion could be a homozygous deletion of a whole or part 
of the gene. GPX1 was tested here for HDs in RCC and 
BC in comparison with RASSF1A and SEMA3B. Us-
ing multiplex PCR, HDs were detected in GPX1 gene 
in these tumors with frequencies of up to 12%, and 
in RASSF1A and SEMA3B with frequencies of up to 11% 
and 8%, respectively. More sensitive quantitative Real 
Time PCR revealed 10–18% of HDs in RCC and BC with-
in the NL3-001 marker closely located to SEMA3B in our 
previous study [14]. Nevertheless, incidence of HDs 
in tumors was similar for these three genes. These data 
support TSG features of GPX1 and suggested that the 
MECA3 potentially harbor TSG(s).
The chromosomal regions around VHL (3p25.3), 
CER (3p21.31), and proximal region in 3p14.2-p13 were 
shown to be a tumor-specific. Region around VHL gene 
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showed AI mainly in RCC and NSCLC. CER was af-
fected mainly in RCC and EOC.
Both putative oncogenes and TSG(s) could 
be located in the MECA3. AI pattern was complex 
in many tumor biopsies and amplification of a sec-
ond allele was frequently (up to 13% in RCC cases) 
observed in addition to LOH. LOH associated with 
amplification in 3p was detected earlier in lung can-
cer by combination of allelotyping with FISH [44]. 
We showed that distribution of amplification events 
was not random along 3p, including an amplification 
peak within the MECA3 region in BC with significant 
statistics (P = 0.03). These data suggested that the 
MECA3 contains both TSG(s) and oncogene(s).
Amplification is one of the possible mechanisms 
of proto-oncogene activation. In this work we stud-
ied amplification of the RHOA also known as ARHA 
gene. Rho small GTPases are members of the Ras-
superfamily. RHOA gene was reported to be involved 
in critical cellular functions such as cell growth, 
development, apoptosis, and cell cyto-architecture 
(the formation of stress fibers, and focal adhesions). 
The gene is also important for cell-cell dissociation 
and motility. RHOA is deregulated during tumor pro-
gression and it is suggested that the pivotal steps 
in this process are adhesion of tumor cells to the 
host cell layers and subsequent migration in cancer 
invasion and metastasis [28, 45]. Activation of RHOA, 
regulating the microfilament network and cadherin-
dependent cell-cell contacts, leads to the induction 
of cellular proliferation, morphological transformation, 
anchorage-independent growth, and tumor formation 
when transformed cells are injected into nude mice. 
Recent evidence has suggested that RHOA could also 
act as a dominant oncogene, since RHOA transgenes 
confer a transformed phenotype on fibroblast cells 
in culture. RHOA exhibited an elevated expression 
on protein and RNA level in BC, EOC and testicular 
tumors [28, 46, 47]. Activating mutations were not 
detected in the coding region of this putative oncogene 
neither in BC, RCC, lung, colon or ovarian carcino-
mas [48]. Over-expression of a gene in certain tumor 
types could be causally associated with the elevated 
gene copy numbers. Here multiplication of the RHOA 
genomic copies in some BC and RCC was reported 
for the first time. The amplification of the RHOA gene 
was shown to be associated with the increased expres-
sion on RNA level in BC, RCC and EOC by us earlier. 
The degree of multiplication/amplification observed 
directly in RHOA gene achieved 2-50 fold in RCC 
and BC. The incidence of amplification events within 
MECA3 in BC achieved 16.5%.
Multiplications and amplifications of the RHOA 
in BC and RCC supported its oncogenic behavior and 
can represent a model of the RHOA activation never 
reported before for this putative oncogene. These ex-
periments also confirmed the hypothesis that TSG(s) 
and oncogene(s) can be closely located and even the 
same gene (RHOA) can sometimes play TSG or onco-
genic role [see also 10 and 49].
3p genes contribute to tumor progression. 
In this study four regions of 3p were affected in the 
major cancer types and were found to be associated 
with progression of certain histological types of tu-
mors. Earlier association with tumor progression was 
revealed mainly for proximal and telomeric regions 
of 3p. Thus, AI in 3p24-p25 markers in BC was found 
to correlate with histological grade [50] and risks 
of five years mortality [51]. Increased frequency of al-
lelic losses of 3p markers in BC was also associated 
with increasing tumor grade [52]. High frequency 
of LOH events in 3p25 and 3p14 markers was shown 
to correlate with the stage of EOC [53]. Allelic losses 
at 3p14 and in the telomeric region of 3p21.3 were 
reported to accumulate predominantly in low differ-
entiated lung adenocarcinoma [54]. 
Here, a systematic study was performed in detail 
using identical set of markers distributed along 3p 
in representative subsets of major epithelial tumors, 
characterized histologically and clinically. In search for 
a possible association of 3p alteration with tumor pro-
gression, the most common histological subtypes were 
considered: clear cell RCC, ductal and lobular BC, 
serous EOC and squamous cell lung cancer. The nine 
3p regions were tested, and allelic alterations in four 
regions, especially the AP20, LUCA, and MECA3, were 
shown to be significantly associated with progression 
of several histological types of tumors. Contribution 
of AP20 and LUCA regions to the progression of clear 
cell RCC, and serous EOC, and association of the 
allelic changes in the MECA3 with advanced stages 
and poor differentiation of serous EOC was proved 
using calculation approach based on tumor samples 
numbers and AI events numbers (Table 4).
Thus, we provided evidence of relationship be-
tween progression of several histological tumor 
types and allelic alterations within the regions in the 
3p21.3 band. Our findings suggest that some genes 
located in these 3p21.3 segments are involved in the 
progression of certain epithelial cancers in addition 
to the well-documented role of 3p genes in the early 
events of neoplasm development [1, 3].
CONCLUSION
As a main result, a novel region frequently affected 
in four major epithelial cancers was localized between 
markers D3S2409 and D3S3667 in the 3p21.3. This 
region (MECA3, major epithelial cancers affected 
region No. 3) covers numerous UniGene clusters, 
including genes involved in vital cell functions and 
carcinogenesis (e.g. MST1, MSTR1/RON, GPX1 and 
RHOA). The homozygous deletions were detected 
in the GPX1 in RCC (12%, 6 of 50 cases) and BC 
(1 of 37 cases). The data suggested that genes with 
oncogenic features are located in the close proximity 
to putative TSG(s) in the MECA3. RHOA multiplication, 
never reported before, can represent a novel mode 
of this protooncogene activation. Significant correla-
tion of allelic alterations in the AP20, MECA3 and LUCA 
regions with tumor progression was found for some 
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common histological tumor subtypes (clear cell RCC, 
serous EOC, and ductal BC).
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